Laudanum toward banning opium tincture or at least requiring the product to be brought within the FDA's regulatory framework. Opium tincture remains in the British Pharmacopoeia, where it is referred to as Tincture of Opium, B.P., Laudanum, Thebaic Tincture, or Tinctura Thebaica, and "adjusted to contain 1% w/v of anhydrous morphine." It is a Class A substance under the Misuse of Drugs Act of 1971. At least one manufacturer (Macfarlan Smith) still produces opium tincture in the U.K. . "Gee's Linctus" is also available from most UK pharmacies, especially the Independent stores. This contains "Opium Tincture", at 0.083ml, per 5ml, and
Personalized medicine of personalised medicine to further fields of medicine, which requires the interdisciplinary cooperation of experts from specific fields of research, such as medicine, clinical oncology, biology, and artificial intelligence. The FDA has already started to take initiatives to integrate personalised medicine into their regulatory policies. An FDA report in October 2013 entitled, “"Paving the Way for Personalized Medicine: FDA’s role in a New Era of Medical Product Development",” in which they outlined steps they would have to take to integrate genetic and biomarker information for clinical use and drug development. They determined that they would have to develop specific regulatory